Literature DB >> 9373269

Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor.

N J Ketley1, P D Allen, S M Kelsey, A C Newland.   

Abstract

The relationship between differentiation of human myeloid cells and apoptosis remains unclear. Recent studies have shown that terminal differentiation need not necessarily lead to the apoptotic demise of myeloid cells, while other studies have shown that induction of differentiation is associated with increased resistance to apoptosis-inducing agents, such as chemotherapy and gamma-irradiation. Such results are pertinent to the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome, where differentiating agents and hemopoietic growth factors are being combined with chemotherapy to enhance response and limit toxicity. To elucidate the factors governing apoptosis in human AML blasts, we have studied the cytotoxic effect of idarubicin on HL60, U937 and KG1 cells, after incubation with all-trans retinoic acid (ATRA), 1, 25(OH)2 D3, and granulocyte-macrophage colony-stimulating factor (GM-CSF ). We show that prior incubation of human myeloid leukemic cells with ATRA or 1,25(OH)2 D3 induced resistance to idarubicin-induced apoptosis, which was modulated by coincubation with GM-CSF. The altered chemosensitivity of cells depended on the degree of G0/G1 cell-cycle arrest induced by incubation with ATRA, 1, 25(OH)2 D3, and GM-CSF and was independent of differentiation status or Bcl-2 oncoprotein expression. These findings suggest that cell-cycle arrest in human leukemic cells can be induced by exogenous agents and may promote drug resistance. Determining the mechanisms by which cell-cycle arrest is induced may permit understanding of the processes by which the cells escape cytotoxic drug-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373269

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Transduction of Fas gene or Bcl-2 antisense RNA sensitizes cultured drug resistant gastric cancer cells to chemotherapeutic drugs.

Authors:  Bing Xiao; Yong-Quan Shi; Yan-Qiu Zhao; Han You; Zuo-You Wang; Xian-Ling Liu; Fang Yin; Tai-Dong Qiao; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  Differential Regulation of Bcl-xL Gene Expression by Corticosterone, Progesterone, and Retinoic Acid.

Authors:  Steve J Morrissy; Haipeng Sun; Jack Zhang; Joshua Strom; Qin M Chen
Journal:  J Biochem Mol Toxicol       Date:  2016-02-25       Impact factor: 3.642

Review 3.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

4.  Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.

Authors:  M Milella; S M Kornblau; Z Estrov; B Z Carter; H Lapillonne; D Harris; M Konopleva; S Zhao; E Estey; M Andreeff
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

5.  Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas.

Authors:  Fang Yin; Yong-Quan Shi; Wei-Ping Zhao; Bing Xiao; Ji-Yan Miao; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

6.  Retinoic acid isomers protect hippocampal neurons from amyloid-beta induced neurodegeneration.

Authors:  M Sahin; S B Karauzum; G Perry; M A Smith; Y Aliciguzel
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

7.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

Authors:  Richard F Schlenk; Konstanze Döhner; Michael Kneba; Katharina Götze; Frank Hartmann; Francesco Del Valle; Heinz Kirchen; Elisabeth Koller; Jörg T Fischer; Lars Bullinger; Marianne Habdank; Daniela Späth; Silja Groner; Bernhard Krebs; Sabine Kayser; Andrea Corbacioglu; Andreas Anhalt; Axel Benner; Stefan Fröhling; Hartmut Döhner
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

8.  Retinoids as a potential treatment for experimental puromycin-induced nephrosis.

Authors:  V Moreno-Manzano; F Mampaso; J C Sepúlveda-Muñoz; M Alique; S Chen; F N Ziyadeh; M C Iglesias-de la Cruz; J Rodríguez; E Nieto; J M Orellana; P Reyes; I Arribas; Q Xu; M Kitamura; F J Lucio Cazana
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

9.  Cell death signaling and anticancer therapy.

Authors:  Lorenzo Galluzzi; Ilio Vitale; Erika Vacchelli; Guido Kroemer
Journal:  Front Oncol       Date:  2011-05-03       Impact factor: 6.244

10.  High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery.

Authors:  Dhara A Patel; Anand C Patel; William C Nolan; Yong Zhang; Michael J Holtzman
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.